Orthofix Medical Q2 sales slightly beat estimates

Orthofix Medical

05/08/2026 12:14

Overview
U.S. medical device maker's Q2 sales rose 4% and slightly beat analyst expectations
Adjusted EBITDA for Q2 missed analyst estimates
Company raised full-year 2026 sales and adjusted EBITDA guidance

Outlook
Orthofix raises 2026 net sales outlook to $845 mln-$855 mln from $838 mln-$848 mln
Company lifts 2026 adjusted EBITDA guidance to $95 mln-$98 mln from $90 mln-$93 mln

Result Drivers
SEGMENT GROWTH - Double-digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction, driven by strong international performance and demand across key platforms
BIOLOGICS MOMENTUM - Biologics stabilized and began to regain momentum, supported by focused commercial execution

Company press release: ID:nBwbXpcLga

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Slight Beat*
$210.90 mln
$209.28 mln (5 Analysts)
Q2 Adjusted EBITDA
Miss
$20.10 mln
$22.24 mln (5 Analysts)
Q2 Gross Margin
 
71.00%
 
Q2 Adjusted Gross Margin
 
71.70%
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Orthofix Medical Inc. is $16.00, about 31.1% above its August 4 closing price of $12.20

Reuters Recommended Reads
Aug 4 - Alphatec Q2 revenue beats estimates on strong surgical case volume
Aug 4 - OrthoPediatrics Q2 revenue rises 15%, beats estimates
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)